A Multi-center Double-blind Parallel-group Placebo-controlled Study of the Efficacy and Safety of Teriflunomide in Patients With Relapsing Multiple Sclerosis Who Are Treated With Interferon-beta
Phase of Trial: Phase III
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Teriflunomide (Primary)
- Indications Multiple sclerosis
- Focus Registrational; Therapeutic Use
- Acronyms TERACLES
- Sponsors Sanofi
- 10 Jun 2017 Biomarkers information updated
- 08 Jan 2013 Status changed from active, no longer recruiting to discontinued, according to a Sanofi media release.
- 14 Dec 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.